TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02659098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 2476 3.0 x 10^5 cells
Description: Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subretinal Delivery System
Description: Participants will receive CNTO 2476 by using the Delivery System.
Study: NCT04776902

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Patients will fill a questionary with 8 questions.
Study: NCT01398098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Description: 32 tablets
Study: NCT04346810

Intervention type: OTHER
Intervention: Patient management suffering of coronavirus infection
Description: Welle-being and stress of the caregivers

Intervention type: OTHER
Intervention: Patient management suffering of coronavirus infection
Description: Welle-being and stress of the caregivers
Study: NCT01667549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of Diet and Flavor Experience
Description: Groups differ in the timing and duration of exposure to flavored food experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of Diet and Flavor Experience
Description: Groups differ in the timing and duration of exposure to flavored food experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of Diet and Flavor Experience
Description: Groups differ in the timing and duration of exposure to flavored food experience.
Study: NCT00909532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150-mg tablets given orally q12h for up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet given orally q12h for up to 48 weeks
Study: NCT01130168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
Study: NCT03276390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hispanic Kidney Transplant Program (HKTP)
Description: The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
Study: NCT02637102

Intervention type: OTHER
Intervention: Not applicable - observational study
Study: NCT04642547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Gefitinib
Description: First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.
Study: NCT03513068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Oxygen Concentrator (POC)
Description: COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
Study: NCT02461862

Intervention type: BEHAVIORAL
Intervention: Application of the Visual Analog Scale of pain
Description: Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain

Intervention type: PROCEDURE
Intervention: Evaluation of blood pressure
Description: Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.

Intervention type: PROCEDURE
Intervention: Evaluation of radial pulse
Description: Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
Study: NCT01209598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 200mg
Description: Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food.
Study: NCT03993275

Intervention type: DEVICE
Intervention: MindMotion GO
Description: Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.

Intervention type: DEVICE
Intervention: MindMotion GO
Description: Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
Study: NCT01224522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visionaire
Description: Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical technique
Description: Implantation of Genesis II Total Knee system by means of standard surgical technique.
Study: NCT04553588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disposal pouch
Description: Medication Disposal Pouch
Study: NCT02335905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline Fosamil
Description: IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
Study: NCT04592796

Intervention type: DEVICE
Intervention: Xiaomi MiBand2
Description: Recording of sleep and activity data to study their association with age.

Intervention type: OTHER
Intervention: Socio-demographic questionnaire
Description: Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.

Intervention type: OTHER
Intervention: EuroQol-5D-5L
Description: Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.

Intervention type: OTHER
Intervention: Mini mental State Examination
Description: Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
Study: NCT03206268

Intervention type: DEVICE
Intervention: SD-OCT and SLP using GDx variable corneal compensation
Description: RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation

Intervention type: DEVICE
Intervention: SD-OCT and SLP using GDx variable corneal compensation
Description: RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
Study: NCT00430742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taranabant
Description: Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taranabant
Description: Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taranabant
Description: Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo capsule once daily. Treatment for 52 weeks.
Study: NCT01791413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot medroxyprogesterone acetate
Description: DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
Study: NCT01932268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
Study: NCT02188537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir 2x 2500 mg p.o. days 1 - 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
Study: NCT00513747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV over 4 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV over 4 hours
Study: NCT04592796

Intervention type: OTHER
Intervention: Tinetti Scale
Description: Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.

Intervention type: OTHER
Intervention: Barthel Index
Description: Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.

Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Assessment (PSQI)
Description: Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
Study: NCT02295332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral placebo capsules to RG7625, according to treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral placebo capsules to RG7625, according to treatment schedule
Study: NCT00513747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Given IV over 30 minutes
Study: NCT02757820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Classic
Description: Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
Study: NCT02295332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7625
Description: oral administration, capsules, single ascending dose according to treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7625
Description: oral administration, capsules, single ascending dose according to treatment schedule
Study: NCT03541447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: A single dose of two 20 mg i.m. injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: A single dose of two 20 mg i.m. injections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of two 20 mg i.m. injections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of two 20 mg i.m. injections.
Study: NCT03895450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Protocol
Description: Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise Protocol
Description: Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Protocol
Description: Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
Study: NCT02051335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Donepezil placebo-matching overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Donepezil placebo-matching overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Donepezil placebo-matching overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Donepezil placebo-matching overencapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study: NCT00678964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg, p.o., once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine and Carboplatin
Description: Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
Study: NCT04238338

Intervention type: OTHER
Intervention: monocyte / lymphocyte ratio
Description: The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average

Intervention type: OTHER
Intervention: monocyte / lymphocyte ratio
Description: The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
Study: NCT00198523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and Tobramycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study: NCT03739801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV
Study: NCT02757820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i- gel
Description: Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Description: Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
Study: NCT03780647

Intervention type: OTHER
Intervention: questionnaire
Description: Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
Study: NCT02706847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study: NCT00675584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide
Description: Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Budesonide
Description: Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
Study: NCT01174264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03739801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01174264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02793310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMEK
Description: The intervention group will receive cornea transplantation by DMEK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSAEK
Description: The usual care / control group will receive cornea transplantation by DSAEK